Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...

A new multi-omic study identifies CR1-positive oligodendrocytes as a key pathological feature in Alzheimer's disease, with ...

Researchers find that a lipid damage signal both activates and limits the complement system during cell death, helping ...

Annexon (NASDAQ:ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026 ...

Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA ...

A study in Aging Cell shows that intermittent fasting extends the lifespan of African turquoise killifish, with males and ...

A data-driven demonstration significantly improves Quantum Error Correction, achieving a 20 percent performance lift by ...

Annexon's stock hinges on the Q4 2026 readout of its Phase 3 ARCHER II trial's month-15 primary endpoint in geographic ...

Pegtarazimod blocks the C1 complex and the initiators of both the classical and lectin pathways of inflammation. The peptide ...

IBM (NYSE: IBM ), the U.S. Department of Energy-funded Quantum Science Center (QSC) at Oak Ridge National Laboratory (ORNL), ...

India stands at a defining moment in its development journey. With an expanding digital economy, ambitious infrastructure ...

Annexon, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter ...